|
1
|
Halfdanarson TR, Rabe KG, Rubin J and
Petersen GM: Pancreatic neuroendocrine tumors (PNETs): Incidence,
prognosis and recent trend toward improved survival. Ann Oncol.
19:1727–1733. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luo G, Liu Z, Guo M, Jin K, Xiao Z, Liu L,
Xu J, Zhang B, Liu C, Huang D, et al: (18)F-FDG PET/CT can be used
to detect non-functioning pancreatic neuroendocrine tumors. Int J
Oncol. 45:1531–1536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bilimoria KY, Tomlinson JS, Merkow RP,
Stewart AK, Ko CY, Talamonti MS and Bentrem DJ: Clinicopathologic
features and treatment trends of pancreatic neuroendocrine tumors:
Analysis of 9,821 patients. J Gastrointest Surg. 11:1460–1469.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H,
Xu Y, Chi T, Zhao H, Wang W, et al: Surgical resection improves the
outcome of the patients with neuroendocrine tumor liver metastases:
Large data from Asia. Medicine (Baltimore). 9:e3882015. View Article : Google Scholar
|
|
5
|
Frilling A, Akerström G, Falconi M, Pavel
M, Ramos J, Kidd M and Modlin IM: Neuroendocrine tumor disease: An
evolving landscape. Endocr Relat Cancer. 19:R163–R185. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Falconi M, Zerbi A, Crippa S, Balzano G,
Boninsegna L, Capitanio V, Bassi C, Di Carlo V and Pederzoli P:
Parenchyma-preserving resections for small nonfunctioning
pancreatic endocrine tumors. Ann Surg Oncol. 17:1621–1627. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valle JW, Eatock M, Clueit B, Gabriel Z,
Ferdinand R and Mitchell S: A systematic review of non-surgical
treatments for pancreatic neuroendocrine tumours. Cancer Treat Rev.
40:376–389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang M, Zeng L, Zhang Y, Su AP, Yue PJ and
Tian BL: Surgical treatment and clinical outcome of nonfunctional
pancreatic neuroendocrine tumors: A 14-year experience from one
single center. Medicine (Baltimore). 93:e942014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kuo EJ and Salem RR: Population-level
analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Ann Surg Oncol. 20:2815–2821. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee LC, Grant CS, Salomao DR, Fletcher JG,
Takahashi N, Fidler JL, Levy MJ and Huebner M: Small,
nonfunctioning, asymptomatic pancreatic neuroendocrine tumors
(PNETs): Role for nonoperative management. Surgery. 152:965–974.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu B, Tang LH, Liu Z, Mei M, Yu R, Dhall
D, Qiao XW, Zhang TP, Zhao YP, Liu TH, et al: α-Internexin: A novel
biomarker for pancreatic neuroendocrine tumor aggressiveness. J
Clin Endocrinol Metab. 99:E786–E795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koprowski H, Steplewski Z, Mitchell K,
Herlyn M, Herlyn D and Fuhrer P: Colorectal carcinoma antigens
detected by hybridoma antibodies. Somatic Cell Genet. 5:957–971.
1979. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu
C, Xu J, Ni Q and Yu X: CA125 is superior to CA19-9 in predicting
the resectability of pancreatic cancer. J Gastrointest Surg.
17:2092–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goonetilleke KS and Siriwardena AK:
Systematic review of carbohydrate antigen (CA 19-9) as a
biochemical marker in the diagnosis of pancreatic cancer. Eur J
Surg Oncol. 33:266–270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheema A, Weber J and Strosberg JR:
Incidental detection of pancreatic neuroendocrine tumors: An
analysis of incidence and outcomes. Ann Surg Oncol. 19:2932–2936.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hijioka M, Ito T, Igarashi H, Fujimori N,
Lee L, Nakamura T, Jensen RT and Takayanagi R: Serum chromogranin A
is a useful marker for Japanese patients with pancreatic
neuroendocrine tumors. Cancer Sci. 105:1464–1471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elisei R, Lorusso L, Romei C, Bottici V,
Mazzeo S, Giani C, Fiore E, Torregrossa L, Insilla AC, Basolo F, et
al: Medullary thyroid cancer secreting carbohydrate antigen 19-9
(Ca 19-9): A fatal case report. J Clin Endocrinol Metab.
98:3550–3554. 2012. View Article : Google Scholar
|
|
18
|
Elisei R, Lorusso L, Piaggi P, Torregrossa
L, Pellegrini G, Molinaro E, Agate L, Bottici V, Pani F, Insilla A
Cacciato, et al: Elevated serum levels of carbohydrate antigen 19.9
(Ca 19.9) is a prognostic factor of death in patients with advanced
medullary thyroid cancer. Eur J Endocrinol. 173:297–304. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo G, Javed A, Strosberg JR, Jin K, Zhang
Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, et al: Modified
staging classification for pancreatic neuroendocrine tumors on the
basis of the American Joint Committee on Cancer and European
Neuroendocrine Tumor Society Systems. J Clin Oncol. 35:274–280.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rindi G, Arnold R, Bosman FT, Capella C,
Klimstra D and Klöppel G: Nomenclature and classification of
neuroendocrine neoplasms of the digestive systemBosman TF, Carneiro
F, Hruban RH and Theise ND: WHO classification of tumours of the
digestive system. Lyon, France: International Agency for Research
on Cancer (IARC); 2010
|
|
21
|
Campana D, Nori F, Piscitelli L,
Morselli-Labate AM, Pezzilli R, Corinaldesi R and Tomassetti P:
Chromogranin A: Is it a useful marker of neuroendocrine tumors? J
Clin Oncol. 25:1967–1973. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zatelli MC, Torta M, Leon A, Ambrosio MR,
Gion M, Tomassetti P, De Braud F, Fave G Delle, Dogliotti L and
Uberti EC degli; Italian CromaNet Working Group, : Chromogranin A
as a marker of neuroendocrine neoplasia: An Italian Multicenter
Study. Endocr Relat Cancer. 14:473–482. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Modlin IM, Gustafsson BI, Moss SF, Pavel
M, Tsolakis AV and Kidd M: Chromogranin A-biological function and
clinical utility in neuro endocrine tumor disease. Ann Surg Oncol.
17:2427–2443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kannagi R: Carbohydrate antigen sialyl
Lewis a-its pathophysiological significance and induction mechanism
in cancer progression. Chang Gung Med J. 30:189–209.
2007.PubMed/NCBI
|
|
25
|
Kannagi R, Sakuma K, Miyazaki K, Lim KT,
Yusa A, Yin J and Izawa M: Altered expression of glycan genes in
cancers induced by epigenetic silencing and tumor hypoxia: Clues in
the ongoing search for new tumor markers. Cancer Sci. 101:586–593.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin K, Xu J, Chen J, Chen M, Chen R, Chen
Y, Chen Z, Cheng B, Chi Y, Feng ST, et al: Surgical management for
non-functional pancreatic neuroendocrine neoplasms with synchronous
liver metastasis: A consensus from the Chinese Study Group for
Neuroendocrine Tumors (CSNET). Int J Oncol. 49:1991–2000.
2016.PubMed/NCBI
|
|
27
|
Li J, Luo G, Fu D, Jin C, Hao S, Yang F,
Wang X, Yao L and Ni Q: Preoperative diagnosis of nonfunctioning
pancreatic neuroendocrine tumors. Med Oncol. 28:1027–1031. 2011.
View Article : Google Scholar : PubMed/NCBI
|
